Basilea Pharmaceutica AG Stock Xetra
Stocks
PK5
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 625M 788M 680M 588M 1.1B 74.34B 1.11B 7.4B 2.88B 36.48B 2.96B 2.89B 126B | P/E 2026 * |
13x | P/E 2027 * | 17.6x |
|---|---|---|---|---|---|
| Enterprise Value | 478M 602M 520M 450M 845M 56.85B 852M 5.66B 2.2B 27.9B 2.26B 2.21B 96.52B | EV / Sales 2026 * |
1.82x | EV / Sales 2027 * | 1.55x |
| Free-Float |
91.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 2018-04-18 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 2019-04-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 2011-11-28 |
| Chairman | 71 | 2013-04-08 | |
Nicole Onetto
BRD | Director/Board Member | 72 | 2017-04-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 770M | |
| -0.22% | -1.14% | -11.88% | -13.09% | 43.51B | |
| +0.76% | +9.42% | +303.09% | +540.82% | 33.29B | |
| -4.74% | -6.31% | +10.75% | -20.99% | 29.9B | |
| -0.47% | -0.35% | +3.38% | +31.20% | 29.34B | |
| +0.06% | +4.36% | +13.31% | +21.11% | 25.42B | |
| -0.02% | +10.18% | - | - | 14.36B | |
| -0.98% | -1.86% | +53.43% | +106.06% | 13.18B | |
| -0.29% | -4.40% | +3.13% | +1.69% | 12.72B | |
| +1.67% | +1.35% | +105.56% | +81.16% | 12.08B | |
| Average | -0.42% | +1.60% | +60.10% | +93.50% | 23.76B | |
| Weighted average by Cap. | -0.63% | +1.76% | +61.93% | +103.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 263M 331M 286M 247M 465M 31.28B 469M 3.12B 1.21B 15.35B 1.24B 1.22B 53.11B | 267M 337M 291M 252M 473M 31.83B 477M 3.17B 1.23B 15.62B 1.27B 1.24B 54.03B |
| Net income | 52.62M 66.34M 57.23M 49.53M 93.07M 6.26B 93.85M 624M 243M 3.07B 249M 244M 10.63B | 39.24M 49.47M 42.68M 36.93M 69.4M 4.67B 69.99M 465M 181M 2.29B 186M 182M 7.93B |
| Net Debt | -147M -185M -160M -138M -260M -17.49B -262M -1.74B -678M -8.58B -696M -681M -29.7B | -209M -264M -227M -197M -370M -24.87B -373M -2.48B -965M -12.21B -989M -968M -42.23B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
